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ThecurrentinvestigationattemptedtoconﬁrmthebeneﬁcialactionsofachemicallycharacterizedRadixAstragalidecoction(AM-
W) against type 2 diabetic (T2D) Sprague-Dawley (SD) rats. Using a case/control design, after 2 months of treatment with AM-
W (500mg/kg, daily i.p.) in T2D rats therapeutic outcomes were compared. Sucrose and Astragalus polysaccharides (ASPs) were
showntoexistinnearlyequalproportionsinAM-W.Bodyweightloss,animprovementininsulinsensitivity,andanattenuationof
fattyliverafterAM-WadministrationinT2Dratswereevident.Surprisingly,bloodsugar,beta-cellfunction,andglucosetolerance
inT2DratsdidnotimprovewithAM-Wtreatment.Furtherinvestigationindicatedthedeleteriouseﬀectsoftheadditionofsucrose
(100 and 500μg/mL) and APSs (500μg/mL) on glucose-stimulated insulin secretion and viability, respectively. In conclusion, a
proper administration dosage and a reduction in the sucrose content are keys to maximizing the merits of this herb.
1.Introduction
To manage type 2 diabetes (T2D), both insulin resistance
and beta-cell dysfunction are two major pathological factors
which need to be controlled [1]. In addition, nonalcoholic
fatty liver disease (NAFLD) is strongly associated with
yet often overlooked in T2D. Uncontrolled NAFLD might
subsequently manifest as hepatic inﬂammation, steatosis
(NASH), cirrhosis, and even carcinogenesis [2].
Traditional Chinese medicine (TCM) frequently pre-
scribes the root of Astragali membranaceus (Radix Astragali
(RA); Huang Qi) in antidiabetes TCM formulae for “qi sup-
plementation” [3]. According to current knowledge, Astra-
galus polysaccharides (APSs) and saponins are two bioactive
constituents of RA found to be beneﬁcial for diabetes
interventions. Administration of puriﬁed APSs can reduce
diabetic hyperglycemia and lead to indirect preservation of
beta-cell function and mass via immunomodulatory eﬀects
on type 1 diabetic mice [4, 5]. Recent studies also showed
that puriﬁed APSs partially restore glucose homeostasis by
an insulin-sensitizing eﬀect in T2D mice and rats [6, 7]
and ameliorate diabetic cardiomyopathy and nephropathy
[8, 9]. Moreover, APSs can also ameliorate alcoholic fatty
liver disease and hepatic endoplasmic reticulum (ER) stress
[10, 11]. Therefore, possible improvement in NAFLD with
APSs can be also expected. On the other hand, Astragalus
saponins also possess potent antiglycation, antioxidant, and
hepatoprotective activities beneﬁcial for diabetes therapy
[12, 13].
As mentioned, there is a close association between
traditional indications and modern pharmacological evi-
dence of the therapeutic value of this herb against diabetes.
However, considering that the RA water extract (AM-W)
is the traditional way of administration, two questions that
remain to be answered are to determine the major bioactive
principle in the RA decoction and whether the beneﬁcial
eﬀects observed with puriﬁed APSs or saponins against T2D
and NAFLD can be directly applied to the RA decoction.2 Evidence-Based Complementary and Alternative Medicine
Therefore, by employing T2D rats, the current investiga-
tion used the chemically deﬁned RA water extract to evaluate
possibleimpactsoninsulinresistance,beta-cellfunction,and
associated NAFLD in rats with T2D.
2.SubjectsandMethods
2.1. Materials. Streptozotocin (STZ) and other chemicals
were purchased from Sigma (St. Louis, MO, USA). Insulin
was purchased from Novo Nordisk (Princeton, NJ, USA).
The TRI reagent was purchased from Invitrogen (Taipei,
Taiwan). Acetonitrile and methanol (LC grade) were pur-
chased from Merck (Darmstadt, Germany). H4IIE cells were
purchased from the Bioresource Collection and Research
Center (BCRC, Taichung, Taiwan). BRIN-BD11 cells were
obtained from Prof. Peter R. Flatt (University of Ulster,
Coleraine, UK).
2.2. Plant Material and Preparation of RA Extracts. Dried
roots of Astragali membranaceus were purchased as plant
material from China and authenticated by Prof. Kuo. A
voucher specimen was deposited at the National Research
Institute of Chinese Medicine (Taipei, Taiwan). RA (600g)
was cut and ground into pieces of about 0.5cm, then
distilled and reﬂuxed with 5L of distilled water for 8 hours
(h). The water extract (approximately 2.8L) was ﬁltered
through 6 layers of cheesecloth and then put into a freeze-
dryer to yield dried powder (AM-W; 198g). In contrast,
the ethanol extract was prepared from 100g of RA with
0.5L of 95% ethanol cooked at 50◦C for 3h three times.
The ﬁnal concentrated crude extract (AM-E) yielded 15.2g.
To characterize the polysaccharides, AM-W (7g/dL) was
submitted to precipitation with an equal volume of ethanol.
Two fractions were obtained, and the upper layer was
collected and concentrated as the ﬁrst fraction, AM-W-F1.
The precipitate was collected by centrifugation and became
AM-W-F2 (2g of precipitate) after washing with ethanol and
acetone prior to drying in a vacuum oven.
2.3. Chemical Analysis by High-Performance Liquid Chro-
matography (HPLC) and Nuclear Magnetic Resonance
(NMR). By employing reference compounds including
astragaloside I and II, isoastragaloside I, and sucrose, the
AM-W and AM-E were analyzed using the following appa-
ratus and conditions: the HPLC proﬁle was obtained from
a Shimadzu 10AVP series system equipped with two pumps
(LC-10ADVP, Shimadzu, Kyoto, Japan), a column oven
(CTO-10ASVP, Shimadzu), an evaporative light scattering
detector (ELSD) (ELSD-LT II, Shimadzu), a two-channel
vacuumdegasser(model2003,BiotechAB,Onsala,Sweden),
an SIL-10AVP automatic injector, an SCL-10AVP system
controller, and a class VP workstation for data analysis.
The procedure employed a separation column (Cosmosil
5C18-AR-II,5μm,4.6 ×250mmI.D.,NacalaiTesque,Kyoto,
Japan)elutedatarateof0.8mL/minbelow25◦C.Themobile
phase consisted of water (A) and acetonitrile (B) using a
gradient program of 0% ∼ 1% (B) at 0 ∼ 10min, 25% ∼
32% (B) at 10 ∼ 25min, 32% ∼ 50% (B) at 25 ∼ 50min,
and 50% ∼ 100% (B) at 50 ∼ 60min. The temperature of
the heated drift tube was 50◦C, and the N2 gas ﬂow-rate was
1.5L/min for the ELSD detector. Equal amounts of sample
solutions were ﬁltered through 0.45-μmﬁ l t e r s( M i l l i p o r e ,
Bedford, MA, USA) prior to the injection with a volume of
20μL.
For the polysaccharide and sucrose analyses, the NMR
technique was employed by measuring 1HN M Ra n d13C
NMR spectra of the test samples.
2.4. Generation of Insulin-Dependent Diabetes Mellitus
(IDDM) and T2D Rats for AM-W Administration. Sprague-
Dawley (SD) rats were purchased from the Animal Center of
NationalYang-MingUniversity,Taipei,Taiwan.Thisresearch
followed the Guide for the Care and Use of Laboratory
Animals (NIH publication, 85–23, revised 1996) and was
approved by the Animal Research Committee at the NRICM.
A d u l tm a l eS Dr a t sw e i g h i n g2 5 0∼ 350g were housed
under controlled conditions (i.e., a 23◦Cr o o mt e m p e r a t u r e ,
controlled humidity, and a light/dark cycle of 12/12h).
Induction of IDDM followed a previous description [14].
Brieﬂy, SD rats were given two shots of STZ (100 and
50mg/kg body weight) by an intraperitoneal (i.p.) injection
on days 0 and 2, respectively. After 1 week, rats with a fasting
blood glucose of >126mg/dL were considered diabetic
according to the deﬁnition of diabetes by the World Health
Organization. Starved diabetic rats then received the vehicle,
AM-W (500 and 1000mg/kg), or insulin (2U/kg). Blood
sugar was monitored every 2 h for up to 10h posttreatment.
T h ep r e p a r a t i o no fT 2 Dr a t sw a sb a s e do nS i r n i v a s a ne t
a l . ’ sm e t h o dw i t hs o m em o d i ﬁ c a t i o n s[ 15]. Brieﬂy, SD rats
were fed high-fat chow (high-fat diet) which was standard
chow supplemented with extra lard (20%, w/w), cholesterol
(1%, w/w), and cholic acid (0.1%, w/w). After 2 weeks of
dietary manipulation, the high-fat-diet rats were i.p. injected
with STZ (50mg/kg). After 4 weeks, the rats were considered
diabetic if the fasting blood sugar was >126mg/dL.
Fourteen diabetic rats were randomly divided into two
groups and received either prepared AM-W or saline (as
the vehicle control). Daily i.p. administration was carried
out with 500mg/kg or an equivalent volume of saline for 2
months. Nine nondiabetic control rats fed the standard diet
also received daily saline administration.
2.5. Intravenous Glucose Tolerance Test (IVGTT). After
overnight starving, glucose (1g/kg) was injected via the tail
vein, and blood sugar was measured at 0, 15, 30, 60, and
120min throughout the test with commercial glucometers
(Bioptik Technology, Taipei, Taiwan). The area under the
curve (AUC) was calculated from the graph of blood glucose
(mg/dL) versus time (min).
2.6. Serum Biochemical Analysis. Blood samples were col-
lected from the tail vein of animals anesthetized with
pentobarbital (30mg/kg, i.p.). Serum triglyceride and total
cholesterol were measured with a FUJI DRI-CHEM 3000
analyzer (Fuji Photo Film, Tokyo, Japan). Serum insulin
was measured with an enzyme-linked immunosorbent assayEvidence-Based Complementary and Alternative Medicine 3
(ELISA) kit (Millipore, Bedford, MA, USA). Both the home-
ostasis model assessment for insulin resistance (HOMA-IR =
fasting blood glucose [mM] × fasting insulin [μU/mL]/22.5)
and HOMA for beta-cell function (HOMA-B = 20 × fasting
insulin [μU/mL]/Fasting blood glucose [mM] − 3.5) were
calculated.
2.7.PathologicalExaminations. Attheendoftheexperiment,
anesthetized animals were sacriﬁced in order to harvest the
liver. A portion of liver was ﬁxed with 4% (w/v) paraformal-
dehyde for a later paraﬃn or frozen-tissue section. For the
qualitative pathological histology, hematoxylin and eosin
(H&E)stainingwasusedtoillustratetheoverallmorphology.
Oil red O (ORO) staining was used to identify the neutral
lipid and fatty acid contents. A red color indicated intra-
cellular triglycerides. Periodic acid-Schiﬀ (PAS) staining was
performedtodeterminetheglycogencontent.Apurplecolor
indicated cellular glycogen.
2.8. Western Blotting. The procedure followed a previous
methodology[16].Inbrief,tissueswereimmersedinice-cold
phosphate-buﬀered saline (PBS) prior to homogenization
with an ice-cold lysis buﬀer. Tissue debris was removed
by centrifugation. Equal amounts of protein (40μg) were
subjected to separation on sodium dodecyl sulfate (SDS)
10%polyacrylamidegels.Followingtransfertonitrocellulose
membranes, blots were blocked with 5% (w/v) nonfat milk
in Tris-buﬀered saline containing 0.1% (v/v) Tween 20
(TBST) for 1h and incubated with primary antibodies
at 4◦C overnight prior to incubation for 1h at room
temperature with the secondary antibody. Finally, results
were visualized after development of the ﬁlm with the aid
of an enhanced chemiluminescence (ECL) kit (Amersham
Biosciences, Uppsala, Sweden). The intensity of the blots was
quantiﬁed by AlphaEaseFC (Alpha Innotech, San Leandro,
CA, USA).
2.9. Statistical Analysis. The eﬀects of the three experimental
manipulationsonvariousparameterswereevaluatedbyone-
way analysis of variance (ANOVA) followed by the Tukey-
Kramer test. Results are expressed as the mean ± S.E.M.
Diﬀerences were considered signiﬁcant at P<. 05.
3. Results
3.1. Polysaccharides and Sucrose Are Two Major Constituents
of the RA Decoction (AM-W). From results of the ELSD
detector, Figure 1(a) compares diﬀerences in chemical con-
stituents of the water (AM-W) and ethanol extracts (AM-E).
The chromatogram of AM-W indicated that most AM-W
constituents were distributed in the highly polar (retention
times (tR)o f0∼ 15min) and medium highly polar (tR of
15 ∼ 30min, the ﬂavonoid glycosides) zones, which diﬀered
from the AM-E chromatogram showing prominent peaks
(tR of 40 ∼ 55min) and components in the low polar zone
(tR of 45 ∼ 67min). Compared to authentic samples, this
study further, respectively, identiﬁed peaks 1 ∼ 3f r o mA M -
E chromatogram as astragaloside II, isoastragaloside I, and
astragaloside I. These results indicated that the AM-E is
mainly composed of characteristic saponins and ﬂavonoids.
In contrast, the AM-W possessed major components,
including water-soluble oligosaccharides and polysaccha-
rides which were further conﬁrmed using HPLC and NMR.
In Figure 1(b), peak 4 was determined to be sucrose (peak 4,
tR 4.759min) with a relative amount of 53.78%, compared
to the sucrose standard. In contrast, peaks 1 ∼ 3w e r e
polysaccharides with relative amounts as follows: peak 1 (tR
3.480min, 8.09%), peak 2 (tR 3.701min, 34.92%), and peak
3( tR 4.087min, 3.21%).
In Figure 1(c), the 1HN M Ra n d13C NMR spectra of
AM-W-F1 were very similar to the characteristic signals of
the sucrose standard. In contrast, the 1Ha n d13CN M R
spectra of AM-W-F2 contained distinctive broad signals
which indicated the presence of polysaccharides [17]w h i c h
belong to the structure of 1,4-α-D-glucan [δC 101.3 (C-1),
78.7(C-4), 74.9 (C-3), 73.1 (C-2), 72.7 (C-5), 62.0 (C-6)].
In Figure 1(d), while IDDM rats injected with saline
showednoeﬀectsonthefastingbloodglucoselevel,adminis-
tration of AM-W to IDDM rats resulted in a dose-dependent
blood sugar reduction within 10h of treatment. In contrast,
an insulin injection led to an acute antihyperglycemic eﬀect
within 2h of treatment which lasted for 10h.
3.2. Therapeutic Eﬃcacy of AM-W Administration against
T2D. According to the Chinese herbal drug safety infor-
mation published by the Committee on Chinese Medicine
and Pharmacy (CCMP), Department of Health (DOH),
Taiwan,ratsreceivingani.p.injectionof500mg/kgoftheRA
decoction for 1 month should experience nonpathological
weightlossduetoareductioninfoodintake[18].Asaresult,
a 2-month administration dosage (AM-W at 500mg/kg;
equivalent to 230mg APS/kg) for T2D rats was executed. A
detailed evaluation of the therapeutic eﬃcacy is illustrated in
Figure 2. In Figure 2(a), the body weight of all three groups
signiﬁcantly increased in the 2-month period. However, it
was noted that rats in the T2D vehicle group grew faster
than those in the nondiabetic group (ND) vehicle group.
Consistently with the CCMP report, administration of AM-
W for T2D signiﬁcantly reduced the body weight gain
compared to untreated T2D rats, and they reached a level
similar to that of the ND group.
In terms of glycemic control, to our surprise, fasting high
blood glucose level in T2D rats did not decrease but was
elevatedintheT2D+AM-Wgroup(P<. 05)(Figure2(b)).
In addition, IVGTT observed in T2D rats did not improve
with AM-W administration (Figure 2(c)). However, the
increaseinHOMA-IRinT2Dratswassigniﬁcantlyalleviated
by AM-W (P<. 01; Figure 2(d)). In contrast, HOMA-
B in T2D rats was actually reduced by AM-W treatment
(P<. 01; Figure 2(e)). By examining changes in the
fasting insulin level at various stages, it was clearly illustrated
that hyperinsulinemia was induced by the high-fat diet,
and impaired insulin secretion was achieved with a low-
dose STZ injection (Figure 2(f)). However, although both
insulin secretion and beta-cell function gradually recovered
during the 2-month period in untreated T2D rats, AM-W4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Polysaccharide and sucroseare onlypresent in thewater extract of RadixAstragali (RA)(AM-W).(a) LC-ELSDchromatograms of
the AM-W (a) and the ethanolic extract (AM-E) (b) with a 70-min retention time. Peak identiﬁcation: 1, astragaloside II; 2, isoastragaloside
I; 3, astragaloside I. (b) LC-ELSD chromatograms of the AM-W (a) and sucrose (b) with a 10-min retention time. Peak identiﬁcation: 1, 2,
and3,polysaccharides;peak4,sucrose.(c)Therepresentative 1HNMRand13CNMRspectraofAM-W-F1andAM-W-F2areillustrated.(d)
Conﬁrmation of the hypoglycemic bioactivity of the AM-W. Insulin-dependent diabetic rats were generated with an initial average glucose
level at 407.2 ± 17.8mg/dL (n = 22). The hypoglycemic eﬀect was evaluated by determining the percentage of the initial fasting glucose level
in each group. Diﬀerences at the same time point were determined by ANOVA followed by the Tukey-Kramer test. ∗P<. 05 was considered
signiﬁcant when compared to the control (vehicle) insulin-dependent diabetes mellitus rats.
administration appeared to lead to the abolishment of such a
recovery process in T2D rats (Figures 2(e) and 2(f)).
As shown in Figure 3(a), hepatocytes in rats fed
with standard diet presented polyhedral morphology with
eosinophilic cytoplasm and a usually central nucleus. In
contrast, hepatocytes in T2D rats possessed diﬀuse microve-
sicular steatosis characteristics and showed loss of cyto-
plasmic eosin. In addition, nucleus was forced to diverge
from central location. AM-W administration attenuated
such pathological histology observed in T2D. Consistently,
substantial amount of intracellular lipid was stained by Oil
red O staining method in the liver section of untreated T2D
while no obvious Oil red O stain could be observed in the
liver section of nondiabetic control. AM-W administration
signiﬁcantly reduced such intracellular lipid accumulation
in T2D rats. Finally glycogen content (as judged by PAS
staining) was also depleted in untreated T2D rats compared
to the nondiabetic controls and attenuated in T2D rats by
AM-W administration.
By examining hepatic protein expression, Figure 3(b)
shows that AMPK activity was inhibited in T2D rats as
judged by a reduction in pAMPK expression compared to
ND rats. AM-W administration was associated with pAMPK
expression at a level similar to that in ND rats. In addition,
while phosphoenolpyruvate carboxykinase (PEPCK) protein
expression was unchanged (Figure 3(c)), both acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS) protein
expressions were reduced in T2D + AM-W rats (Figures 3(d)
and 3(e)).
3.3. Counteracting Eﬀects of the Combination of Sucrose and
APS on the Viability and Glucose Response of BRIN-BD11
Cells. In Figure 4(a), a signiﬁcant reduction of cell viability
(∗∗P<. 01) was observed in BRIN-BD11 cells cultured
with either APS (500μg/mL) alone or in combination with
sucrose (500μg/mL) for 48h. In Figure 4(b), the presence
of APS (100μg/mL) alone enhanced insulin secretion in
response to high glucose (16.7mM) compared to the
normal culture control. However, the presence of sucrose
(100μg/mL) led to a reduction in basal insulin secretion
and the abolishment of glucose responsiveness. In addition,
the beneﬁcial eﬀect of APS on glucose responsiveness was
also compromised in the presence of sucrose (Figure 4(b)).
Finally, the above culture conditions did not inﬂuence the
cellular insulin content of BRIN-BD11 cells (Figure 4(c)).
4. Discussion
The RA decoction is traditionally prepared by water extrac-
tion. Diﬀerent from ethanol extraction which contains
mainly nonpolysaccharides, APSs appear to be the major
bioactiveconstituent,atapproximately30% ∼47%(w/w),in
the RA decoction (AM-W). On the other hand, a signiﬁcant
amount of sucrose, approximately 50% (w/w), also exists in
the AM-W. By employing IDDM rats, the dose-dependent
hypoglycemic activity of the AM-W was conﬁrmed in the
current investigation. Such a ﬁnding is consistent with
another report [9] and suggested that diﬀerent from insulin’s6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Therapeutic eﬃcacy of the water extract of Radix Astragali (AM-W) for type 2 diabetes (T2D). Once induced T2D rats were
identiﬁed, the following biochemical parameters were evaluated before and after 2 months of AM-W treatment. (a) Body weight (g); (b)
fasting blood sugar (mg/dL); (c) intravenous glucose tolerance test (IVGTT) for which results were calculated as the area under the curve
(AUC); (d) the insulin resistance index for which results are presented as HOMA-IR; (e) beta-cell function index for which results are
presented as HOMA-IR; (f) fasting serum insulin (ng/mL). Diﬀerences were determined by ANOVA followed by the Tukey-Kramer test. For
bodyweight, ∗P<. 05wasconsideredsigniﬁcantwhencomparedtothebodyweightbeforeAM-Wtreatment.Fortheremainingparameters,
∗P<. 05 compared to the nondiabetic group (ND) and P<. 05 for the comparison between T2D and T2D + AM-W (500mg/kg) rats.Evidence-Based Complementary and Alternative Medicine 7
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Figure 3:LiverhistopathologyandhepaticproteinlevelanalysisafterthewaterextractofRadixAstragali(AM-W)administration.(a)Atthe
end of AM-W administration, representative liver histopathology was examined and illustrated. Representative pictures from photography,
H&E staining, oil-red O staining, periodic acid-Schiﬀ staining, and Masson’s trichrome of control (ND), type 2 diabetes (T2D), and T2D +
AM-W groups are shown. In addition, hepatic proteins from each group were extracted to measure the expressions of (b) AMP kinase
(AMPK) phosphorylated at Thr172 (pAMPK), (c) phosphoenolpyruvate carboxykinase (PEPCK), (d) acetyl CoA carboxylase (ACC), and
(e) fatty acid synthase (FAS). Each blot was quantiﬁed, converted to the relative ratio of actin, and presented as the mean ± SEM (n ≥ 3
in each group). Diﬀerences were determined by ANOVA followed by the Tukey-Kramer test. ∗P<. 05 was considered signiﬁcant when
compared to ND rats. P<. 05 was considered signiﬁcant when T2D and T2D + AM-W rats were compared.
action, the immediate hypoglycemic eﬀect of the AM-W was
mild but unaﬀected by the presence of sucrose.
In terms of administration routes for Astragalus decoc-
tion or its bioconstituents, compared with oral admin-
istration, injection method appeared to provide similar
bioactivities. For example, consistent with the traditional
indications that RA consumption could stimulate the
immune system and improve cardiovascular health, clinical
Astragalus injection promoted the recovery of hemopoietic
function in patients with chronic aplastic anemia [19].
Incidence of cardiac events was also lower in congestive
heart failure (CHF) patients being given Astragalus injection
[20]. Moreover, reduced amounts of RA decoction or RA
constituents via injection could be employed to achieve
similar bioactivity provided by oral administration [21, 22].
As a result, i.p. injection was decided to be employed for
current experimental model of T2D. After administering the
AM-W for 2 months, the current results demonstrated that
various pharmacological eﬀects of the AM-W were consis-
tent with previous works, including the insulin-sensitizing
eﬀect, stabilization of serum cholesterol (data not shown),
and attenuation of hepatic triglyceride accumulation and
glycogen loss in T2D rats [6, 10, 18]. Consistent with Zou
et al.’s observations, the level of activated AMPK decreased
in skeletal muscle of diabetic rats induced by a high-fat diet
plus STZ [23]. In the present study, results also showed
that the level of activated AMPK in the liver was less in
T2Drats,whereasAM-Wadministrationwasassociatedwith
greateractivatedAMPKlevels.Therefore,ourdataagreewith
previous ﬁndings that APS administration results in both
glycogen resynthesis and improved AMPK activities in T2D
rats [23]. In addition, combining the observations that AM-
W administration repressed both ACC and FAS expressions
[24], the current results suggest that attenuation of fatty liver
by the AM-W might be a result of suppression at proximal
steps of hepatic lipogenesis and restoration of normal fatty
acid oxidation activity [25].
However, to our surprise, the fasting blood glucose level
of T2D + AM-W rats had not improved after 2 months of
treatment. Moreover, despite the beneﬁcial eﬀects of APSEvidence-Based Complementary and Alternative Medicine 9
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Figure 4: The eﬀects of Astragalus polysaccharides (APS) and sucrose alone or in combination on the viability, insulin secretion, and cellular
insulin content of BRIN-BD11 cells at 48h posttreatment. After treatment for 48h, (a) the cell viability, (b) glucose-stimulated insulin
secretion, and (c) cellular insulin content of BRIN-BD11 cells were measured. Data are presented as the mean ± SEM (n ≥ 4 in each group).
∗P<. 05 was considered signiﬁcant compared to the viability of untreated control or respective basal insulin secretion (1.1mM glucose).
P<. 05 was considered signiﬁcant compared to the insulin secretion of the untreated control.
on both the beta-cell mass and function in type 1 diabetes
reported by others [5, 26], the current results indicated that
beta-cell function deteriorated after AM-W administration.
We speculated that the excessive sucrose content in the AM-
W might be the key reason for the reduction in beta-cell
function after AM-W treatment, because various studies
demonstrated the deleterious eﬀects of sucrose and fructose
consumption on beta-cell mass and functions [27–29]. By
employing glucose-responsive BRIN-BD11 cells, the impact
of the presence of sucrose on glucose-stimulated insulin
secretion was evident. Moreover, the beneﬁcial eﬀect on
BRIN-BD11 cells provided by APSs was also compromised
bythepresenceofanequalamountofsucrose.Therefore,the
possibility that administration of sucrose-rich AM-W led to
aworseningofbeta-cellfunctioninT2Dratsexists.However,
a reduction in cell viability was also observed in the presence
of a high concentration of APSs. Although the APS content
in the current investigation was much lower than that of
any previous report, we still could not rule out the potential
inﬂuence of APSs in the AM-W on the pancreatic beta-cell
mass in T2D rats.
RA (Huang Qi) is a very important herb in TCM
applications and is frequently used as a dietary supplement.
A statistical analysis of TCM prescription frequency for10 Evidence-Based Complementary and Alternative Medicine
diabetes therapy from the database of the Taiwan National
Health Insurance (2002-2003) also revealed that RA is the
second highest single-drug to be prescribed for caring for
DM outpatients at TCM clinics in Taiwan [30]. In China,
6 of 7 herbal drug products, containing RA as one of the
ingredients, were approved by the Chinese health regulatory
agency for commercial purposes [31]. Our investigation
indicatedthattheRAdecoctionpossessesseveralantidiabetic
characteristicssimilartothoseofpuriﬁedAPSs.Asaresult,it
should be safe to say that consumption of the RA decoction
could beneﬁt type 2 diabetics in some way. However,
the current investigation also pointed out the potential
deleterious eﬀect of the AM-W on beta-cell function due to
the coexistence of sucrose. To our knowledge, this is the ﬁrst
report investigating the potential impact of the two major
constituents in the RA decoction on beta-cell functions.
Nevertheless,itshouldalsoberealizedthattheconsistentuse
of a single herb (the RA decoction) for diabetes intervention
is a very rare situation. Whether such a high sucrose content
exists in commercialized TCM products remains unknown.
Yet, according to the current results, it would be logical to
expect that the potency and consistency of RA-containing
TCM formulae could be further enhanced by removing
sucrose from those decoctions.
In conclusion, the RA decoction contains beneﬁcial APSs
for T2D management and can be also developed as an
anti-NAFLD agent. To achieve consistent eﬃcacy, employing
puriﬁed Astragalus polysaccharides or a sucrose-depleted
RA-included decoction might be a good option to maximize
the merits of such a valuable TCM herb.
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